Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

International journal of ophthalmology Pub Date : 2025-06-18 eCollection Date: 2025-01-01 DOI:10.18240/ijo.2025.06.12

Wael Ahmed Ewais, Lamia Samy Ali, Fayrouz Aboalazayem

{"title":"Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy.","authors":"Wael Ahmed Ewais, Lamia Samy Ali, Fayrouz Aboalazayem","doi":"10.18240/ijo.2025.06.12","DOIUrl":null,"url":null,"abstract":"Aim: To describe the influence of adding topical nepafenac to both; oral eplerenone and intravitreal aflibercept on serous foveal detachment in eyes with central serous chorioretinopathy (CSCR).Methods: This retrospective cohort study included 31 eyes with non-resolving and recurrent CSCR that have been treated between 2015 and 2022 at Kasr Alainy Hospital. They were subdivided into Group A, which had been treated with a combination of systemic eplerenone, intravitreal aflibercept and topical nepafenac, and Group B, which had been treated with a combination of systemic eplerenone and intravitreal aflibercept (without topical nepafenac). Our outcome measures included changes in the best corrected visual acuity (BCVA), central subfield macular thickness (CMT) and serous detachment height (SDH) at baseline and at 2mo after treatment.Results: Group A included 16 eyes. BCVA improved significantly from a logMAR of 0.62±0.44 to 0.42±0.47 (P=0.03), CMT decreased significantly from 401±61 to 301±100 µm, and SDH decreased significantly from 188±81 to 71±100 µm. Group B included 15 eyes. BCVA improved significantly from a logMAR of 0.68±0.39 to 0.55±0.62 (P=0.03), CMT decreased significantly from 411±39 µm to 334±92 µm, and SDH decreased significantly from 191±88 to 121±74 µm. There was a significant difference between changes in BCVA, CMT, and SDH between the two groups.Conclusion: Using topical nepafenac in combination with both systemic eplerenone, and intravitreal aflibercept may provide better results in the treatment of CSCR.","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 6","pages":"1064-1070"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120463/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.06.12","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To describe the influence of adding topical nepafenac to both; oral eplerenone and intravitreal aflibercept on serous foveal detachment in eyes with central serous chorioretinopathy (CSCR).

Methods: This retrospective cohort study included 31 eyes with non-resolving and recurrent CSCR that have been treated between 2015 and 2022 at Kasr Alainy Hospital. They were subdivided into Group A, which had been treated with a combination of systemic eplerenone, intravitreal aflibercept and topical nepafenac, and Group B, which had been treated with a combination of systemic eplerenone and intravitreal aflibercept (without topical nepafenac). Our outcome measures included changes in the best corrected visual acuity (BCVA), central subfield macular thickness (CMT) and serous detachment height (SDH) at baseline and at 2mo after treatment.

Results: Group A included 16 eyes. BCVA improved significantly from a logMAR of 0.62±0.44 to 0.42±0.47 (P=0.03), CMT decreased significantly from 401±61 to 301±100 µm, and SDH decreased significantly from 188±81 to 71±100 µm. Group B included 15 eyes. BCVA improved significantly from a logMAR of 0.68±0.39 to 0.55±0.62 (P=0.03), CMT decreased significantly from 411±39 µm to 334±92 µm, and SDH decreased significantly from 191±88 to 121±74 µm. There was a significant difference between changes in BCVA, CMT, and SDH between the two groups.

Conclusion: Using topical nepafenac in combination with both systemic eplerenone, and intravitreal aflibercept may provide better results in the treatment of CSCR.

查看原文本刊更多论文

依普利酮、阿布西贝和尼帕尼对中枢性浆液性脉络膜视网膜病变的影响。

目的：探讨外用尼帕芬对两者的影响；口服埃普利酮和玻璃体内注射阿布利塞对中枢性浆液性脉络膜视网膜病变（CSCR）眼浆液性中央凹脱离的影响。方法：本回顾性队列研究纳入了2015年至2022年在Kasr Alainy医院治疗的31只未消退和复发的CSCR眼睛。他们被细分为A组，使用全身性肾上腺皮质酮、玻璃体腔内注射阿布利西普和外用尼帕芬酸联合治疗；B组，使用全身性肾上腺皮质酮和玻璃体腔内注射阿布利西普（不外用尼帕芬酸）联合治疗。我们的结果测量包括基线和治疗后2个月的最佳矫正视力（BCVA）、中央亚区黄斑厚度（CMT）和严重脱离高度（SDH）的变化。结果：A组16只眼。BCVA从logMAR的0.62±0.44显著改善到0.42±0.47 (P=0.03)， CMT从401±61显著降低到301±100µm， SDH从188±81显著降低到71±100µm。B组15只眼。BCVA从logMAR的0.68±0.39显著改善到0.55±0.62 (P=0.03)， CMT从411±39µm显著降低到334±92µm， SDH从191±88显著降低到121±74µm。两组患者BCVA、CMT、SDH变化差异有统计学意义。结论：外用neafenac联合全身epleenone和玻璃体内aflibercept治疗CSCR效果较好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of ophthalmology Medicine-Ophthalmology

CiteScore

2.50

自引率

7.10%

发文量

3141

审稿时长

4-8 weeks

期刊介绍： · International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online). This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed, PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166. IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO); Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President, Chinese Academy of Engineering. International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of AAO/PAAO) et al. Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society). Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press). Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics). Associate Editors-in-Chief include: Prof. Ning-Li Wang (President Elect of APAO); Prof. Ke Yao (President of Chinese Ophthalmological Society) ; Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ; Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA); Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society); Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA); Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA). IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles, both basic and clinical papers. Instruction is Welcome Contribution is Welcome Citation is Welcome Cooperation organization International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.